Elemental analysis is a process of detection and quantification of elemental compounds, molecular species and elements. This analysis technique is a part of analytical chemistry and can be qualitative and quantitative in nature. Sample types tested for trace elements comprises of aqueous, non-aqueous, organic and non-organic materials. For organic chemists, elemental analysis refers to CHNX analysis, which is used to determine the purity and structure of a compound. In this technique, a sample is burnt in excess of oxygen and thereby collecting combustion products like carbon dioxide, nitric acid and water. The masses of these products are used to determine composition of the sample. Ultra trace analysis and elemental trace analysis detection range from parts per million (ppm), to parts per billion (ppb) and parts per trillion (ppt) levels, using updated techniques and instruments. Some of the major technologies used for elemental analysis include inductively coupled plasma mass spectrometry, inductively coupled plasma optical emission spectrometry, X-ray Fluorescence and X-ray Diffraction among others.

Some of the key driving factors for elemental analysis market are increasing concern for food safety, increasing usage of X-ray fluorescence in clinical research and growing R&D funding in life sciences. Moreover, this technology has a wide range of application areas in different segments of industry and thus has a major market worldwide. There are other geographical drivers which are also responsible for the growth of the market. In addition, demand from emerging markets across India and China are expected to create opportunities for elemental analysis market in the future. However, high cost of elemental analyzers and urge for efficient professionals act as major restraints to the growth of the market.

Global elemental analysis market can be broadly classified on the basis of types, technology, applications and geography. By types, the market for elemental analysis is segmented into organic and inorganic. The market is divided by technology into destructive and non-destructive technologies. Moreover, elemental analysis has different application areas including food and beverage testing, life sciences, environment testing and geology among others.

Currently North America is dominating the market for elemental analysis in terms of revenue, followed by Europe and Asia-Pacific. The major factor responsible for immense development of elemental analysis market in North America is rapid technological advancement of this technique in various application areas, such as food and beverage, biotechnology, chemical and semiconductor industries among others. However, Asia Pacific is anticipated to grow at a significant rate in the future, primarily due to increasing awareness for elemental analysis in China and India coupled with rising demand from applied markets. Furthermore, strategic expansion by manufacturers in China and use of modern analysis technique in Chinese medicines are likely to develop the market for elemental analysis in Asia Pacific.

The elderly are highly prone to contracting skin diseases such as various forms of ulcers due to their significantly reduced flow of blood and overall immunity against diseases. The number of geriatrics in all nations has been on the rise owing to multiple factors, and a rise in their number is a direct call to action for all related healthcare organizations, products, and services. This includes the tissue engineered skin substitute providers and makes the above the top driver for its market.

The number of patients suffering from skin diseases and ulcers is also increasing within younger demographics. The CDC, for instance, stated in 2015 that close to 900,000 people are affected by DVT per year. A large number of patients were additionally being diagnosed with venous diseases per year, further boosting the need for tissue engineered skin substitutes.

The market is, however, restrained by over competitiveness between local manufacturers and their globally prominent counterparts. The local manufacturers can offer tissue engineered skin substitutes at a much lower price than global ones, forcing the latter to drop prices and consequently their profit margins. This will affect the market’s rate of research and development in the long run.

These drivers and restraints are expected to converge to result in a CAGR of 17.2% for the global market of tissue engineered skin substitutes between 2015 and 2023. This market is expected to be valued at US$1.24 bn by the end of 2016, and US$3.87 bn by 2023.

North America Continues to Show Strong Demand for Tissue Engineered Skin Substitutes

The need for tissue engineered skin substitutes in North America has consistently been high over the past few years. It is expected to generate US$1.96 bn in revenue for tissue engineered skin substitute players by 2023. A key reason prompting the use of tissue engineered skin substitutes in North America is the very high prevalence of vascular diseases. The region holds an especially high proportion of the geriatric, diabetic, and obese demographics and thus requires tissue engineered skin substitutes to a higher degree than other major regions.

Europe is another key region for tissue engineered skin substitute players. This region shows a similarly high demand as that shown by North America, although at a smaller revenue cap. The highest demand for tissue engineered skin substitutes at the moment, however, comes from Asia Pacific. The revenue earned by tissue engineered skin substitute providers in this region is expected to progress at a CAGR of 18.3% from 2015 to 2023. Key reasons for the high proliferation of tissue engineered skin substitute players in Asia Pacific is the growing geriatric population in nations such as South Korea and Japan, along with the rapidly increasing investments made by governments into the market.

Ulcers have consistently been the leading application segment for tissue engineered skin substitutes. By the end of 2023, nearly US$2.1 bn will be generated by tissue engineered skin substitute players through ulcer treatment alone. This segment is also expected to grow at a robust CAGR of 17.5% within 2015 and 2023.

The same applies to other skin disorders that are growing in prevalence across the globe. Most dermatology organizations such as the ADA have made their predictions, all of which point to a growing number of patients with skin disorders. The ADA, for instance, in 2013, released findings of a study that stated at least one in every five U.S. citizens will suffer from a skin disorder in their lifetime. This makes the development of dermatology solutions such as tissue engineered skin substitutes a matter of high concern.

Iraq is one of the fastest growing economies in Middle East and North Africa (MENA) attributed by the flourishing oil sector that is helping the domestic government to improve health care services. The Iraq health care system is managed by mixed initiatives of public and private sector; wherein the public sector covers approximately 75% of all health care facilities, and the private sector represents the remaining 25%. Iraq has improved its health care system after years of war. The booming petroleum industry is helping the Government of Iraq to invest in improving health care services and develop medical infrastructure. Furthermore, the burden of non-communicable diseases is increasing significantly, which has created a significant demand for medical equipment and services in Iraq. This industry assessment focuses on understanding the growth prospects and current situation of various surgical procedures that are major applications of medical devices.

Among the major surgical procedures considered to be performed in the country, that include cardiac procedures, general surgeries, orthopedic surgeries, neurosurgeries and reconstructive surgeries; cardiac procedures emerged as the segment leader in terms of revenue in 2013. The substantiating factors behind such rapid growth of the segment are rise in prevalence of diabetes population susceptible to cardiovascular diseases and increasing base of target patient population requiring surgical procedures for their survival. According to the Iraqi Diabetes Association (IDA), there were around 1.2 million cases of diabetes in Iraq in 2014. Approximately 387 million people suffer from diabetes globally, of these more than 37 million people are from MENA. IDA also estimated that this number would increase to 68 million by 2035. Consequently, the rise in prevalence of diabetes population would lead to increase in cardiovascular diseases in Iraq. Other risk factors associated with cardiovascular diseases such as early onset hypertension, dyslipedemia, and obesity also contribute significantly towards increasing the overall CVD burden in Iraq. Thus, with the increase in number of cardiovascular patients and stable industry condition in Iraq, the flourishing healthcare industry trend of the country is expected to continue in the near future.

Iraq healthcare industry is highly fragmented in nature, due to the presence of many international as well as domestic market players including distributors. However, few multinational market players such as Siemens Healthcare, Phillips Healthcare, and Medtronic plc, among others dominate the medical device industry in Iraq. Other players (including manufacturers and distributors) operating in the industry include Rudolf Riester GmbH, Minas Company, Ismailiya Medical Co., Albanna Group, GE Healthcare, MAQUET and Stryker Corporation; that cumulatively accounted for a share of over 40% in 2013. The market leadership of such players was attributed to several factors such as commercial availability of products, superior distribution channels, and demand satisfying supply capabilities.

Presently, the global market for X-ray systems and technologies is witnessing steady growth due to high prevalence and increasing incidence of cardiovascular, respiratory, gastrointestinal, and genitourinary, and several other disorders. Additionally, the global aging population and commercialization of new, improved and technologically advanced X-ray systems would boost demand, which would in turn fuel the growth of the X-ray market. New and advanced X-ray systems increasingly find applications in breast cancer imaging, detection of tumor outgrowths, and several other chronic disorders and diseases. Demand for advanced systems is rapidly rising due to the need for early diagnosis to ensure effective treatment and/or management of the disease. Recent technological advancements in the diagnostics industry has led to the introduction of several advanced X-ray systems such as mobile and handheld digital systems, direct digital radiography systems, direct & indirect flat panel detection based systems, and CMOS and CCD based digital systems.

Stationary or fixed X-ray systems held the largest share of 60.1% of the global X-ray market in 2013. Stationary or fixed X-ray systems have been in use for a long time — since the discovery of first X-ray based imaging and diagnostic systems — in developed as well as less developed nations in the world. This is due to portable systems, especially handheld X-ray systems, were launched recently in the global market. However, portable systems are expected to witness high growth rate during the forecast period, and would outperform the stationary X-ray systems segment by 2022. Hospitals, diagnostic laboratories and health care professionals have started installing and using several portable especially mobile systems globally as these systems offer portability and ease of use over stationary systems particularly for bedside imaging or home health care. Based on X-ray technologies, the digital X-ray systems segment held the largest share of 69.1%, followed by the analog systems segment in the global X-ray market in 2013. The computed radiography systems sub-segment held the largest share of the digital X-ray systems segment in 2013. However, the direct digital radiography systems segment is expected to register fastest growth during the forecast period and outperform the CR systems segment by 2022. This is majorly due to introduction and increased acceptance of advanced direct digital X-ray systems that offer several advantages over traditional systems such as low exposure to harmful X-rays, better image quality, and less time consumption.

According to World Health Organization (WHO) estimates, cardiovascular diseases accounted for around 17.3 million deaths in 2008, and the number is likely to increase to 23.3 million deaths each year by 2030. The low to middle income countries are the largest affected regions, accounting for 80% of all the deaths due to cardiovascular diseases across the world. According to WHO estimates, over 9 million people were suffering from tuberculosis globally in 2013. The number of TB cases increased by 4.7% from 8.6 million in 2012 to 9 million in 2013. The total number of deaths due to TB also increased by 15% from 1.3 million in 2012 to 1.5 million in 2013. According to WHO estimates, around 60% to 90% school children and 80% to 90% adults (age group: 19 – 34) suffer from dental cavities. Moreover, the global incidence rate of oral cancer ranges between one to ten cases per 100,000 individuals. At present, several X-ray technologies are increasingly being used for early detection of several chronic diseases and disorders to ensure effective diagnosis and treatment. However, high cost of advanced digital systems and implementation of legal provisions (e.g. affordable care act) that promote cost containment/cost cutting strategies could have a negative impact on the growth of the market in the near future. Moreover, presence of large underserved population in most of the emerging economies of the world would continue to provide future opportunities for the growth of the market during the forecast period.

North America held the largest share of 34.6% of the global X-ray market in 2013, followed by Asia Pacific and Europe. North America comprises the developed economies of the U.S. and Canada that have a large number of elderly individuals suffering from various cardiovascular, orthopedic, genitourinary, and abdominal diseases and disorders. Hence, rising occurrence of various disorders along with high awareness and affordability among people and well established health care infrastructure in the region increases demand for advanced X-ray systems. However, Asia Pacific is expected to register the fastest growth during the forecast period from 2014 to 2022 due to rapid growth expectation of this market in countries such as China and India. The key factor attributed to the high growth of the market in the region is the presence of high geriatric population suffering from a range of respiratory, cardiovascular, gastrointestinal, and genitourinary disorders requiring urgent diagnosis and effective treatment. Other factors include rising government support, increasing awareness and affordability, and corresponding demand for advanced X-ray systems across major economies in the region.

The growing expenditure on healthcare coupled with the rising geriatric population have triggered the demand for convenient and cost-effective medical care worldwide. The model of urgent care has been designed for providing opportune access to cost-effective and quality healthcare services across the globe the Urgent Care Association of America puts forth the definition of urgent care centers of UCCs as the medical care centers that deliver health care services on a walk-in or no appointment basis for treating injuries or illnesses that are over the scope of conventional primary care and are also at the same time not life threatening. Maximum of the urgent care centers deliver services for moderate injuries, trauma, illness, monitoring, screening, lab tests, physicals, routine vaccinations, and occupational medicine. The rising geriatric population across the globe along with the prevalence of inexpensive medical care services are the core drivers for the growth of the global market for urgent care centers. Moreover, the growing investments in the market for urgent care centers has been resultant of the increase in the number of advanced urgent care centers across the world, therefore impacting the market confidently. On the other hand, the nonappearance of physicians and the growing cost of initial establishment of urgent care centers are expected to constrain the growth of the market in the years ahead.

The global urgent care centers market is expected to witness a 3.80% CAGR between 2014 and 2020. The market is projected to rise to a valuation of US$30.5 bn by the end of 2020 from a worth US$23.5 bn in 2013.

The global market for urgent care centers has been segment in terms of services into monitoring and screening, diagnostic, routine vaccination, physical, trauma and injury, and illness. The foremost revenue was produced through illness services that held for the leading share in the global urgent care centers market closely trailed by the injury segment. Maximum of the visits in the urgent care centers market were recorded for illness circumstances of which the upper five conditions were upper respiratory tract infections, urinary tract infections, fever & cold, pharyngitis, and otitis media. They collectively held for over 50% of illness related visits.

North America to Rule Undefeated

Region-wise, the market has been segmented into Asia Pacific, Europe, North America, and the Rest of World. North America was the leading market with the majority share in the global urgent care centers market closely trailed by Europe. North America is projected to maintain its governing position through the forecasted period. This can be credited to the mounting adoption of urgent care centers for non-emergency conditions. The upsurge in demand for walk-in health services and the increase in demand for moneymaking medical care are also causative of the growth of the urgent care centers market in North America. On the other hand, in the Asia Pacific region, India, Japan, Australia, China, and New Zealand are the main countries that provide huge prospects to companies operating in the market. In Rest of the World (RoW), Mexico, Brazil, South Africa, Turkey, Israel, and UAE are the foremost countries where the urgent care centers market is anticipated to record noteworthy growth.

DNA sequencing is defined as the process of determining the order of four nucleotide bases i.e. adenine, guanine, cytosine and thymine within the strand of deoxyribonucleic acid (DNA) molecule. DNA sequencing technology is extensively used for drug development since its success in the human genome project, making it an essential tool for genetic analysis. Additionally, innovations in the microarrays, bioinformatics and other important tools have increased the area of application and services of DNA sequencing in drug discovery. On the basis of sequencing tools, DNA sequencing in drug discovery market is fragmented into four major segments namely instruments, consumables, services and workflow.

The market for DNA sequencing in drug discovery can also be analyzed on the basis of consumables used during the procedure. Various types of consumables such as chemicals, reagents and probes, DNA polymerase, primes and automated DNA sequencers are being used in DNA sequencing process. On the basis of services and analysis, DNA sequencing in drug discovery market is analyzed into following segments namely:

Shotgun sequencing

High throughput sequencing

Re-sequencing

Single pass analysis

Sample process and primer walking

Bacterial identification

Besides, the workflow in DNA sequencing in drug discovery market majorly includes bioinformatics software, computational chemistry and biology modeling. These products aid in increasing the efficiency of process and understanding of the molecule in study. They can be used in analyzing and solving chemical problems during the study.

Presently, DNA-sequencing in drug discovery market is focused on developing drugs for oncology, various vaccines and infectious diseases. The market of DNA-sequencing in drug discovery is increasing at a rapid pace majorly driven by increasing applications of microarrays and polymerase chain reaction techniques and increasing research and development of personalized medicines. Moreover, technological breakthroughs and increasing applications of automated sequencer is also helping the market to grow. The growth of DNA-sequencing in drug discovery market is restrained by few factors such as partial scope of microarrays for pathogen enumeration, high cost of supporting products and incompatibility problems with current bioinformatics tools.

North America is currently leading the DNA-sequencing in drug discovery market followed by Europe majorly due to increasing government funds towards the associated research and development. In U.S., the national human genome research institute (NHGRI), part of national institute of health (NIH) granted more than USD 14 million in grants for developing new and innovative DNA sequencing technologies to be used in drug discovery for various fatal diseases. The Asia-Pacific market will grow at a faster pace owing to increasing funds by the government of countries such as India, Japan, China and Australia for research and development activities. Key players are seeking for market opportunities in potential geographies such as Asia-Pacific and Latin America, either through organic or inorganic route. For instance, Thermo Fisher Scientific recently acquired Life Technologies for USD 13.6 billion in cash which is sought to have a major impact on the global DNA sequencing industry.

Epithelial cell adhesion molecule (EpCAM), is a cell surface protein or antigen, which is considered an highly expressed element in most of the key cancer types, including prostate, breast, colon, lung, gastric, ovarian, and pancreatic cancer. As a result, EpCAM antagonists are considered as well-established as an ideal therapeutic target and market for cancer of epithelial origin. The growing focus of leading players on research and development activities and technological advancements in the healthcare sector are projected to encourage the growth of the global EpCAM antagonists market throughout the forecast period.

The research study offers a detailed analysis of the global EpCAM antagonists market, presenting insights into the important factors that are projected to impact the growth of the overall market in the near future. In addition, the driving factors, restraints, and the promising opportunities in the global EpCAM antagonists market have been highlighted in order to offer a strong understanding of the overall market. The product segmentation, innovations and developments, latest trends, major applications, key regional segments, and the competitive landscape of the global EpCAM antagonists market have been discussed in the research report.

The tremendously rising prevalence of different types of cancer across the globe is one of the key factors estimated to fuel the growth of the global EpCAM antagonists market throughout the forecast period. In addition, the rising government initiatives and spending on research and development activities for cancer treatment are expected to accelerate the growth of the overall market in the next few years. Furthermore, the constant development in the field of recombinant DNA technology is projected to offer promising opportunities for the key players operating in the global market for EpCAM antagonists.

However, the lack of awareness regarding the availability of advanced therapeutics, especially in developing economies and the high cost of overall cancer treatments are some of the key factors likely to restrict the growth of the global EpCAM antagonists market in the coming few years.

Global EpCAM Antagonists Market: Regional Outlook

The global market for EpCAM antagonists can be classified in terms of geography to offer an in-depth analysis. The key regional segments include Asia Pacific, Europe, North America, and the Rest of the World. Among these, North America is projected to lead the overall market and account for a large share throughout the forecast period. The presence of a large number of leading players operating in this region is one of the major factors estimated to supplement the growth of the EpCAM antagonists market in the next few years.

Furthermore, the rising number of cancer cases in this region is another factor encouraging the growth of the market in the next few years. On the other hand, Asia Pacific is projected to witness significant growth in the coming years.

Some of the key players operating in the EpCAM antagonists market across the globe are Johnson and Johnson, Amgen, Inc., Fresenius Biotech, The University of Hong Kong and American Association for Cancer Research, and Trion Pharma GmbH. The increasing number of players entering the global market and focusing on research and development activities are some of the factors estimated to accelerate the growth of the global EpCAM antagonists market throughout the forecast period.

Posts navigation

Text Widget

This is a text widget. The Text Widget allows you to add text or HTML to your sidebar. You can use a text widget to display text, links, images, HTML, or a combination of these. Edit them in the Widget section of the Customizer.